[The effect of multimodality induction therapy for locally advanced non-small cell lung cancer].

Abstract

In this study we analyzed induction therapy for locally advanced non-small cell lung cancer. Eligible patients had mediastinoscopic proven N2 disease and T4 with mediastinal involvement. From January 1997 to May 2005, 56 patients entered the study. They received 2 cycle chemotherapy (platinums based 2 or 3 drugs), in 32 patients with concurrent radiotherapy followed by surgery. Response rates were 57.1%. Fifty-one patients underwent surgery. A radical resection was possible in 39 patients. Complication occurred in 14 patients (27.5%). Overall 5-year survival was 27.5%. In N2 disease, there was no statistically significant difference in survival between the induction group and the historical group. In T4 disease, overall 5-year survival was 30.2% for the induction group and 5.2% for historical group. There was significant difference in survival between the groups (p < 0.05).

• Authors: T Yamada, Y Nakashima, M Tanahashi, Y Hikosaka, H Yoshitomi, H Niwa
• Journal: Kyobu geka. The Japanese journal of thoracic surgery (Kyobu Geka) Vol. 58 Issue 11 Pg. 969-75 (Oct 2005) ISSN: 0021-5252 [Print] Japan
• PMID: 16235845 (Publication Type: English Abstract, Journal Article)

Chemical References

• Mitomycins
• Vinblastine
• Carboplatin
• Paclitaxel
• Cisplatin

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Carboplatin (administration & dosage)
• Carcinoma, Non-Small-Cell Lung (drug therapy, mortality, radiotherapy, surgery)
• Cisplatin (administration & dosage)
• Combined Modality Therapy
• Drug Administration Schedule
• Female
• Humans
• Lung Neoplasms (drug therapy, mortality, radiotherapy, surgery)
• Male
• Middle Aged
• Mitomycins (administration & dosage)
• Paclitaxel (administration & dosage)
• Pneumonectomy
• Prognosis
• Survival Rate
• Vinblastine (administration & dosage)